← Back
Data updated: Mar 10, 2026
SMITH AND NEPHEW
CardiovascularOncologyGastroenterology
SMITH AND NEPHEW is a biotechnology company focused on Cardiovascular, Oncology, Gastroenterology.
1965
Since
22
Drugs
-
Trials
158
Approved (2yr)
Key Drugs
No active drugs
Recent Activity
HEPARIN SODIUM 2026-02-20
Labeling
HEPARIN SODIUM 2026-02-20
Labeling
FLUOROURACIL 2026-02-10
Labeling
FLUOROURACIL 2026-02-10
Labeling
FLUOROURACIL 2026-02-05
Labeling
FLUOROURACIL 2026-02-05
Labeling
FLUOROURACIL 2026-02-05
Labeling
FLUOROURACIL 2026-02-05
Labeling
FLUOROURACIL 2026-02-05
Labeling
FLUOROURACIL 2026-02-05
Labeling
SEC Filings
Pro
Loading...
Therapeutic Focus
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Cardiovascular 50%
3 drugs
Oncology 17%
1 drugs
Gastroenterology 17%
1 drugs
Neurology 17%
1 drugs
Pipeline Strength Pro
Loading...
Competitors Pro
Active (7)
Discontinued (15)
HEPARIN SODIUM FUROSEMIDE HALOPERIDOL HYDROXYZINE HYDROCHLORIDE TRIMETHOBENZAMIDE HYDROCHLORIDE METOCLOPRAMIDE HYDROCHLORIDE HYDRALAZINE HYDROCHLORIDE PROCHLORPERAZINE EDISYLATE PROCAINAMIDE HYDROCHLORIDE DOPAMINE HYDROCHLORIDE HEPARIN LOCK FLUSH PHENYTOIN SODIUM AMINOPHYLLINE DROPERIDOL METHYLDOPATE HYDROCHLORIDE
Company Info
- First Approval
- 1965-06-04
- Latest
- 2019-08-26
- Applications
- 44